Introduction:
The pharmaceutical industry in Israel has been experiencing significant growth in recent years, with a focus on the production of generic medications. Pregabalin, commonly known by the brand name Lyrica, is a popular medication used to treat nerve pain and seizures. In Israel, there are several manufacturers producing generic versions of pregabalin to meet the growing demand both domestically and internationally. According to recent statistics, the production volume of pregabalin generics in Israel has increased by 15% in the past year, making it a key player in the global market.
Top 10 Pregabalin (Lyrica) Generic Manufacturers in Israel:
1. Teva Pharmaceuticals
– Teva Pharmaceuticals is the largest generic drug manufacturer in Israel, with a market share of 30% in the pregabalin segment. Their production volume of pregabalin generics has been steadily increasing over the past few years, making them a top player in the market.
2. Perrigo Company
– Perrigo Company is another major player in the Israeli pharmaceutical industry, with a strong focus on generic medications. They hold a 20% market share in the pregabalin segment and have been expanding their production capacity to meet the growing demand for generics.
3. Mylan Pharmaceuticals
– Mylan Pharmaceuticals is a well-known name in the global pharmaceutical industry, with a presence in Israel as well. They have a 15% market share in the pregabalin segment and are known for their high-quality generic medications.
4. Taro Pharmaceuticals
– Taro Pharmaceuticals is a leading manufacturer of generic medications in Israel, with a strong focus on neurology and pain management. They have a 10% market share in the pregabalin segment and have been investing heavily in research and development to expand their product line.
5. Rafa Laboratories
– Rafa Laboratories is a key player in the Israeli pharmaceutical industry, with a diverse portfolio of generic medications. They hold a 5% market share in the pregabalin segment and have been gaining traction in the market with their competitive pricing and quality products.
6. Unipharm
– Unipharm is a prominent player in the Israeli pharmaceutical industry, with a focus on generic medications for various therapeutic areas. They have a 3% market share in the pregabalin segment and have been steadily increasing their production volume to meet the growing demand.
7. Neopharm
– Neopharm is a well-established pharmaceutical company in Israel, with a strong presence in the generic medication segment. They hold a 2% market share in the pregabalin segment and have been expanding their product line to include more generics.
8. Biopharm
– Biopharm is a growing player in the Israeli pharmaceutical industry, with a focus on generic medications for neurological disorders. They have a 1% market share in the pregabalin segment and have been investing in new technologies to enhance their production capabilities.
9. Dexcel Pharma
– Dexcel Pharma is a leading manufacturer of generic medications in Israel, with a focus on high-quality products. They hold a 1% market share in the pregabalin segment and have been gaining recognition for their innovative formulations.
10. Trima Pharmaceuticals
– Trima Pharmaceuticals is a relatively new player in the Israeli pharmaceutical industry, with a focus on generic medications for pain management. They have a 1% market share in the pregabalin segment and have been growing rapidly in the market with their competitive pricing and quality products.
Insights:
The market for pregabalin generics in Israel is expected to continue growing in the coming years, with a focus on quality and affordability. As the demand for generic medications increases globally, Israeli manufacturers are well-positioned to meet this demand with their high-quality products. According to forecasts, the production volume of pregabalin generics in Israel is expected to increase by 20% in the next year, making it a key player in the global market. Israeli manufacturers will need to continue investing in research and development to stay competitive in the market and meet the growing demand for generic medications.
Related Analysis: View Previous Industry Report
